Taysha Gene Therapies Price to Sales Ratio 2020-2025 | TSHA
Historical PS ratio values for Taysha Gene Therapies (TSHA) over the last 10 years. The current P/S ratio for Taysha Gene Therapies as of April 14, 2026 is .
| Taysha Gene Therapies P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2026-04-15 | 6.00 | 185.36 | |
| 2025-12-31 | 5.50 | $0.03 | 169.92 |
| 2025-09-30 | 3.27 | $0.02 | 140.37 |
| 2025-06-30 | 2.31 | $0.03 | 77.07 |
| 2025-03-31 | 1.39 | $0.03 | 49.49 |
| 2024-12-31 | 1.73 | $0.03 | 50.46 |
| 2024-09-30 | 2.01 | $0.06 | 35.12 |
| 2024-06-30 | 2.24 | $0.09 | 25.36 |
| 2024-03-31 | 2.87 | $0.12 | 23.75 |
| 2023-12-31 | 1.77 | $0.18 | 9.81 |
| 2023-09-30 | 3.16 | $0.15 | 21.15 |
| 2023-06-30 | 0.66 | $0.11 | 5.92 |
| 2023-03-31 | 0.80 | $0.07 | 10.73 |
| 2022-12-31 | 2.26 | 0 | 0.00 |
| 2022-09-30 | 1.93 | 0 | 0.00 |
| 2022-06-30 | 3.72 | 0 | 0.00 |
| 2022-03-31 | 6.52 | 0 | 0.00 |
| 2021-12-31 | 11.65 | 0 | 0.00 |
| 2021-09-30 | 18.62 | 0 | 0.00 |
| 2021-06-30 | 21.20 | 0 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.290B | $0.010B |
| Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |